

MARIA SANTORO - CURRICULUM VITAE

PERSONAL DATA

Date of birth: May 24th 1973

Place of birth: Agrigento, Italy

Citizen: Italy

Languages: Italian, English, French

E-mail address: santormaria@gmail.com; maria.santoro@uniroma2.it

Phone number: 0672596572

FORMAL EDUCATION

July 2006: PhD in Medical Immunobiology, University of Rome “Tor Vergata”.

January 2004: Professional Licence in Biology, University of Viterbo “La Tuscia”.

July 2001: BA in Biological Sciences, University of Rome “Tor Vergata”.

1991: High school diploma, “Ettore Majorana” High School, Latina.

CURRENT POSITION

29 November 2019-ongoing: Assistant Professor (RTD-B) at the Laboratory of Virology, Department of Experimental Medicine, Faculty of Medicine University of Rome “Tor Vergata”.

ACCADEMIC POSITIONS

1 December 2015–28 November 2019: Post-doctoral research assistant at the Laboratory of Virology, Department of Experimental Medicine, Faculty of Medicine University of Rome “Tor Vergata”.

13 July 2017: She obtained the National Scientific Qualification to function as associate professor in Italian Universities (Procedure 2016-2018 of The Italian Ministry for Education, University and Research - MIUR). Competition sector: 06A3 – Microbiology and Clinical Microbiology. Qualification validity: From 13 July 2017 to 13 July 2023.

2013-2015: Researcher at the Laboratory of Virology, Department of Experimental Medicine and Surgery, Faculty of Medicine University of Rome “Tor Vergata”.

2008-2013: Research fellow at the Laboratory of Virology, Department of Experimental Medicine and Surgery, Faculty of Medicine University of Rome “Tor Vergata”.

June-August 2010: Visiting scholar at the Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL.

RESEARCH INTERESTS AND ACTIVITIES

Main Interests: impact of the antiretroviral treatments on HIV infection; mechanisms of resistance to antiretroviral drugs; HIV/AIDS epidemiology; fitness and viral evolution; genotypic, structural and functional analysis of viral proteins.

She supervises the research activities of several graduate students and PhD students at the Chair of Virology, University of Rome “Tor Vergata”.

PUBLICATIONS

H index (Google Scholar): 23

Total citations (Google Scholar; last access: 16/09/2020): 2037

She published **355** scientific publications: **108** *in extenso* on national and international journals, **2** acts concerning workshops, **1** monography, **1** chapter book and **243** abstracts presented at national international scientific meetings (of which **38** in published proceedings).

For her research activities, she has received 13 National and International Awards.

SCIENTIFIC COLLABORATION WITH ITALIAN AND FOREIGN INSTITUTIONS

She cooperates with many national and international recognized scientific researchers in several grants from the Italian National Institute of Health, the Ministry of University and Scientific Research, and the European Community.

PROFESSIONAL MEMBERSHIPS

2019-2020: Member of the panel of the Spanish guidelines for HIV drug-resistance.

2017-ongoing: Member of the Steering Committee of the Italian PRESTIGIO (Pazienti con Infezione da HIV-1 con RESistenza agli Inibitori della Trascrittasi inversa, dell'InteGrasI e della PrOteasi virale) Registry.

2016-ongoing: Member of the Steering Committee of the ARCA (Antiviral Response Cohort Analysis) Database.

2015-ongoing: Member of the Steering Committee of the ICONA (Italian Cohort of antiretroviral-naive patients) Study group.

2012-ongoing: Member of the panel of the Italian guidelines for the management of HIV-1 infected patients "Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1".

The undersigned authorizes the processing of personal data, in accordance with the provisions of Law 675/96 and 196/2003.

Rome, 16/09/2020



Maria Santoro

MARIA (MERCEDES) SANTORO - LIST OF *IN EXTENSO* PUBLICATIONS

1. A Artese, V Svicher, G Costa, R Salpini, V Chiara Di Maio, M Alkhatib, FA Ambrosio, **Maria Mercedes Santoro**, YG Assaraf, S Alcaro, and F Ceccherini-Silberstein. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Accettato su Drug Resistance update. **IF 11.650**
2. Fokam J, Takou D, Semengue ENJ, Teto G, Beloumou G, Dambaya B, **Santoro Maria Mercedes**, Mossiang L, Billong SC, Cham F, Sosso SM, Temgoua ES, Nanfack AJ, Moudourou S, Kamgaing N, Kamgaing R, Ngako Pamen JN, Etame MMN, Bissek AZ, Elat JN, Moussi EE, Colizzi V, Perno CF, Ndjolo A; VIROFORUM. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens. Antimicrob Resist Infect Control. 2020 Aug 26;9(1):143. doi: 10.1186/s13756-020-00799-2. PMID: 32843050; PMCID: PMC7449072. **IF 1.499**
3. J Fokam, D Takou, EJ Semengue Ngoufack, G Teto, G Beloumou Angong, B Dambaya, Maria Santoro, L Mossiang, SC Billong, F Cham, SM Sosso, E Temgoua, A Nanfack, S Moudourou, N Kamgaing, R Kamgaing, J Nounouce Ngako Pamen Bouba Haman, MP Mpoudi Ngolle, AC Z-K Bissek, JB Elat, EE Moussi, V Colizzi, CF Perno, A Ndjolo. First Case of Dolutegravir and Darunavir/r Multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: Lessons and Implications in the era of transition to Dolutegravir-based regimens. Accettato su Antimicrobial Resistance & Infection Control. **IF 3.610**
4. L Fabeni*, **Maria Mercedes Santoro***, P Lorenzini, S Rusconi, N Gianotti, A Costantini, L Sarmati, A Antinori, F Ceccherini-Silberstein, and A d'Arminio Monforte, A Saracino, and E Girardi, on behalf of the Icona Foundation Study Cohort. Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy . 2020;12(8):E791. Published 2020 Jul 23. doi:10.3390/v12080791 ***Equal contribution; Corresponding author.** **IF 3.816**
5. Armenia D, Bouba Y, Gagliardini R, Gori C, Bertoli A, Borghi V, Gennari W, Micheli V, Callegaro AP, Gazzola L, Bruzzone B, Giannetti A, Mazzotta M, ergori A, Mastrociosa I, Colafigli M, Lichtner L, di Biagio A, Maggiolo F, Rizzardini G, D'Arminio Monforte A, Andreoni M, Mussini C, Antinori A, Ceccherini-Silberstein F, Perno CF, **Maria Mercedes Santoro**, for the Italian INI-Surveillance Group. Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. Accettato su Journal Clinical Virology. **Corresponding author.** **IF 2.777**
6. J Fokam, D Takou, G Teto, OP Kome, SE Nforbih, **Maria Mercedes Santoro**, ES Ngoufack, M Eyongetah, D Palmer, ET Fokunang, CN Fokunang, V Colizzi, CF Perno, and A Ndjolo. Pre-treatment Drug Resistance and HIV-1 Genetic Diversity in the Rural and Urban Settings of Northwest-Cameroon. PLoS One. 2020;15(7):e0235958. Published 2020 Jul 21. doi:10.1371/journal.pone.0235958. **IF 2.776**
7. Fokam J, Nangmo A, Wandum C, Takou D, Santoro MM, Nlend AN, Ateba FN, Ndombo PK, Kamgaing N, Kamta C, Essiane A, Lambo V, Fokunang C, Mbanya D, Colizzi V, Perno CF, Ndjolo A. Programme quality indicators of HIV drug resistance among adolescents in urban versus rural settings of the centre region of Cameroon. AIDS Res Ther. 2020 May 12;17(1):14. doi: 10.1186/s12981-020-00270-7. PubMed PMID: 32398107. Free su PUBMED. **IF 2.240**
8. Canetti D., Galli L., Gianotti N., Celotti A., Calza L., Gagliardini R., Rusconi S., Modica S., Cenderello G., Ferrara M., **Santoro Maria Mercedes**, Zazzi, M., and Castagna, A., on behalf of PRESTIGIO Study Group. Simplification to High Genetic Barrier 2-Drug Regimens in People Living

With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry. *Journal of acquired immune deficiency syndromes* (2020), 84(4), e24–e28. <https://doi.org/10.1097/QAI.0000000000002378>. **IF 3.475**

9. Semengue ENJ, **Santoro Maria Mercedes**, Ndze VN, Dambaya B, Takou D, Teto G, Nka AD, Fabeni L, Wiyeh A, Ceccherini-Silberstein F, Colizzi V, Perno CF, and Fokam J. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol. *Syst Rev*. 2020 Apr 25;9(1):93. doi: 10.1186/s13643-020-01356-z. PubMed PMID: 32334643. **IF. 1.76**

10. F Saladini, A Giannini, F Giammarino, F Maggiolo, F Vichi, GM Corbelli, A Galli, A Bigoloni, A Poli, MM Santoro, M Zazzi, and A Castagna. In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in multidrug resistant HIV-1 infected patients. *J Antimicrob Chemother*. 2020;dkaa178. doi:10.1093/jac/dkaa178. **IF 5.439**

11. D Armenia, D Di Carlo, P Flandre, Y Bouba, V Borghi, F Forbici, A Bertoli, C Gori, L Fabeni, W Gennari, C Pinnetti, A Mondì, S Cicalini, R Gagliardini, A Vergori, R Bellagamba, V Malagnino, F Montella, M Colafigli, A Latini, R Marocco, M Lichtner, M Andreoni, C Mussini, F Ceccherini-Silberstein, A Antinori, CF Perno, and **Maria Mercedes Santoro**. HIV multi-drug resistance is still a relevant issue despite its dramatic drop over the years. *Antimicrob Chemother*. 2020;75(5):1301-1310. doi:10.1093/jac/dkz554. **Corresponding author. IF 5.439**

12. C Soulie, **Maria Mercedes Santoro**, A Storto, B Abdi, C Charpentier, D Armenia, A Jary, F Forbici, A Bertoli, W Gennari, M Andreoni, C Mussini, A Antinori, CF Perno, V Calvez, F Ceccherini-Silberstein, D Descamps, and AG Marcelin. Prevalence of Doravirine associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. *Antimicrob Chemother*. 2020;75(4):1026-1030. doi:10.1093/jac/dkz553. **IF 5.439**

13. R Scutari, C Alteri, I Vicenti, D Di Carlo, V Zuccaro, F Incardona, V Borghi, A Bezenchekf, M Andreoni, A Antinori, CF Perno, A Cascio, A De Luca, M Zazzi, and **Maria Mercedes Santoro**, on behalf of the ARCA (Antiviral Response Cohort Analysis) study Group. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. *Glob Antimicrob Resist*. 2020;20:163-169. doi:10.1016/j.jgar.2019.07.015. **Corresponding author. IF 2.706**

14. J Fokam, SM Sosso, B Yagai, SC Billong, Re Djubgang Mbadie, R Kamgaing Simo, SV Edimo, A Durand Nka, A Tiga Ayissi, Jf Yimga, D Takou, S Moudourou, M Ngo Nemb, JBE Nfetam, **Maria Mercedes Santoro**, CF Perno, V Colizzi, and Alexis Ndjolo. Viral Suppression in Adults, Adolescents and Children receiving Antiretroviral Therapy in Cameroon: Adolescents at High Risk of Virological Failure in the Era of “Test and Treat”. *AIDS Research and Therapy* 2019 Nov 19;16(1):36. **IF 2.357**

15. J Fokam, **Maria Mercedes Santoro**, D Takou, AE Njom Nlend, P Koki Ndombo, N Kamgaing, C Kamta, A Essiane, SM Sosso, A Ndjolo, V Colizzi, and CF Perno. Evaluation of Treatment Response, Drug Resistance and HIV-1 Variability among Adolescents on First- and Second-Line Antiretroviral Therapy: An observational and prospective study in the Centre Region of Cameroon (EDCTP READY-Study). *BMC Pediatr*. 2019;19(1):226. Published 2019 Jul 5. doi:10.1186/s12887-019-1599-z. **IF 2.042**

16. C Alteri, R Scutari, C Stingone, G Maffongelli, M Brugneti, F Falasca, S Martini, A Bertoli, O Turriziani, L Sarmati, N Coppola, M Andreoni, **Maria Mercedes Santoro**, CF Perno, F Ceccherini-Silberstein, and V Svicher. Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: their dynamic decay and correlations with immunological parameters and virological success". J Clin Virol. 2019 Aug;117:61-67. **IF 3.101**
17. S Rusconi*, **Maria Mercedes Santoro***, A Antinori, S Bonora, A Cingolani, N Gianotti, F Ceccherini Silberstein, A Tavelli, A d'Arminio Monforte, and A Cozzi-Lepri for the Icona Foundation Study Group. Is the rate of virological failure to cART continuing to decline in recent calendar years? J Clin Virol. 2019 Jul;116:23-28. doi: 10.1016/j.jcv.2019.04.009. Epub 2019 May 3. ***Equal contribution.** **IF 3.101**
18. L Fabeni, C Alteri, G Berno, R Scutari, N Orchi, G De Carli, A Bertoli, L Carioti, C Gori, F Forbici, R Salpini, A Vergori, R Gagliardini, S Cicalini, A Mondì, C Pinnetti, L Mazzuti, O Turriziani, M Colafigli, V Borghi, F Montella, A Pennica, M Lichtner, E Girardi, M Andreoni, C Mussini, A Antinori, F Ceccherini-Silberstein, CF Perno, and **Maria Mercedes Santoro**; the SENDIH Study group. Characterization of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. Sex Transm Infect. 2019 May 10. pii: sextrans-2019-054017. doi: 10.1136/sextrans-2019-054017. **IF 3.346**
19. Armenia D, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, and **Santoro Maria Mercedes**; ICONA Foundation Study Group. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. Antivir Ther. 2019 Apr 12. doi: 10.3851/IMP3309. [Epub ahead of print] PubMed PMID: 30977466. **Corresponding author.** **IF 2.146**
20. Takou D, Fokam J, Teto G, **Maria Mercedes Santoro**, Ceccherini-Silberstein F, Nanfack AJ, Sosso SM, Dambaya B, Salpini R, Billong SC, Gori C, Fokunang CN, Cappelli G, Colizzi V, Perno CF, and Ndjolo A. HIV-1 Drug Resistance Testing is Essential for Heavily-Treated Patients Switching from First- to Second-Line Regimens in Resource-Limited Settings: Evidence from Routine Clinical Practice in Cameroon. BMC Infect Dis. 2019 Mar 12;19(1):246. doi: 10.1186/s12879-019-3871-0. PubMed. PMID: 30871487; PubMed Central PMCID: PMC6419466. **Free article. IF 2.62**
21. C Soulié, **Maria Mercedes Santoro**, C Charpentier, A Storto, D Paraskevis, D Di Carlo, W Gennari, G Sterrantino, M Zazzi, CF Perno, V Calvez, D Descamps, F Ceccherini-Silberstein, and AG Marcelin. Rare occurrence of doravirine resistance associated mutations in HIV-1-infected treatment-naïve patients. J Antimicrob Chemother. 2019 Mar 1;74(3):614-617. doi: 10.1093/jac/dky464. PMID:30476106 **IF 5.217**
22. C Alteri, R Scutari, A Bertoli, D Armenia, C Gori, G Fabbri, CM Mastroianni, C Cerva, A Cristaudo, I Vicenti, B Bruzzone, M Zazzi, M Andreoni, A Antinori, V Svicher, F Ceccherini-Silberstein, CF Perno, and **Maria Mercedes Santoro**. Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. Virus Genes. 2019 Feb 22. doi: 10.1007/s11262-019-01649-z. **IF 1.542**
23. Antinori A, **Santoro Maria Mercedes**, Gagliardini R, Marchetti G, Mondì A, Cento V, Perno CF, Andreoni M; Two-Drug Antiretroviral Regimens expert panel. Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1

infected patients. *New Microbiol.* 2019 Feb 20;42(1). [Epub ahead of print] PubMed PMID: 30785209. **Free article. Review. IF 1.568**

24. Pougá L, **Santoro Maria Mercedes**, Charpentier C, Di Carlo D, Romeo I, Artese A, Alcaro S, Antinori A, Wirlden M, Perno CF, Ambrosio FA, Calvez V, Descamps D, Marcelin AG, Ceccherini-Silberstein F, Lambert-Niclot S. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T). *Chem Biol Drug Des.* 2019 Jan;93(1):50-59. doi: 10.1111/cbdd.13378. Epub 2018 Nov 27. PMID: 30103267 **IF 2.328**

25. C Alteri, L Fabeni, R Scutari, G Berno, D Di Carlo, C Gori, A Bertoli, A Vergori, I Mastroianni, R Bellagamba, C Mussini, M Colafigli, F Montella, A Pennica, CM Mastroianni, E Girardi, M Andreoni, A Antinori, V Svicher, F Ceccherini-Silberstein, CF Perno, and **Maria Mercedes Santoro**. Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence. *Sci Rep.* 2018 Oct 24;8(1):15739. doi: 10.1038/s41598-018-34058-7. PubMed PMID: 30356083; PubMed Central PMCID: PMC6200748. **Free PMC Article. IF 4.122**

26. Spertilli Raffaelli C, Rossetti B, Paglicci L, Colafigli M, Punzi G, Borghi V, Pecorari M, **Santoro Maria Mercedes**, Penco G, Antinori A, Zazzi M, De Luca A, Zanelli G. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor. *J. Antimicrob. Chemother.* 2018 Jun 25. doi: 10.1093/jac/dky211. **IF. 5.217**

27. Armenia D, Zaccarelli M, Borghi V, Gennari W, Di Carlo D, Giannetti A, Forbici F, Bertoli A, Gori C, Fabeni L, Pinnetti C, Marocco R, Latini A, Ceccherini-Silberstein F, Mastroianni CM, Mussini C, Antinori A, Perno CF, and **Santoro Maria Mercedes**. Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. *J Clin Virol.* 2018 Jul; 104:61-64. doi: 10.1016/j.jcv.2018.04.001. Epub 2018 Apr 3. PMID: 29738896. **IF. 3.051**

28. Fokam J, Bellocchi MC, Armenia D, Nanfack AJ, Carioti L, Continenza F, Takou D, Temgoua ES, Tangimpundu C, Torimiro JN, Koki PN, Fokunang CN, Cappelli G, Ndjolo A, Colizzi V, Ceccherini-Silberstein F, Perno CF, and **Santoro Maria Mercedes**. Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. *Medicine (Baltimore).* 2018 Mar;97(13):e0176. doi: 10.1097/MD.00000000000010176. PubMed PMID: 29595649. **Free PMC Article. IF. 1.803**

29. **Santoro Maria Mercedes**, Di Carlo D, Armenia D, Zaccarelli M, Pinnetti C, Colafigli M, Prati F, Boschi A, Antoni AMD, Lagi F, Sighinolfi L, Gervasoni C, Andreoni M, Antinori A, Mussini C, Perno CF, Borghi V, Sterrantino G. Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. *Antivir Ther.* 2018;23(3):249-257. doi: 10.3851/IMP3197. PMID: 28935850 **Corresponding author. IF. 2.146**

30. Libonati A, Di Taranto V, D'Agostini C, **Santoro Maria Mercedes**, Di Carlo D, Ombres D, Gallusi G, Favalli C, Marzo G, Campanella V. Comparison of coronal leakage of different root canal filling techniques: an ex vivo study. *J Biol Regul Homeost Agents.* 2018 Mar-Apr;32(2):397-405. PubMed PMID: 29685025. **IF. 1.558**

31. Fabeni L, Alteri C, Di Carlo D, Orchi N, Carioti L, Bertoli A, Gori C, Forbici F, Continenza F, Maffongelli G, Pinnetti C, Vergori A, Mondì A, Ammassari A, Borghi V, Giuliani M, De Carli G, Pittalis S, Grisetti S, Pennica A, Mastroianni CM, Montella F, Cristaudo A, Mussini C, Girardi E, Andreoni M, Antinori A, Ceccherini-Silberstein F, Perno CF, and **Santoro Maria Mercedes**; SENDIH Study Group; SENDIH (Studio Epidemiologico Nuove Diagnosi Infezione da HIV) Study Group. Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14. *J Antimicrob Chemother.* 2017 Oct 1;72(10):2837-2845. doi: 10.1093/jac/dkx231. PubMed PMID: 29091206. **IF. 5.071**

32. Fabeni L, Berno G, Fokam J, Bertoli A, Alteri C, Gori C, Forbici F, Takou D, Vergori A, Zaccarelli M, Maffongelli G, Borghi V, Latini A, Pennica A, Mastroianni CM, Montella F, Mussini C, Andreoni M, Antinori A, Perno CF, and **Santoro Maria Mercedes**, on behalf of the Resistance Study group. Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains. *J Clin Microbiol.* 2017 Sep;55(9):2827-2837. doi: 10.1128/JCM.00656-17. Epub 2017 Jul 12. **Free PMC Article. IF. 3.712**
33. Soo-Yon Rhee, Vici Varghese, Susan P. Holmes,, **Maria Mercedes Santoro**,, Sergio Carmona, Ravindra K. Gupta, and Robert W. Shafer. Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen. *EBioMedicine.* 2017 Apr;18:225-235. doi: 10.1016/j.ebiom.2017.03.024. Epub 2017 Mar 19. **Free PMC Article. IF. 6.183**
34. Armenia D, Di Carlo D, Calcagno A, Vendemiati G, Forbici F, Bertoli A, Berno G, Carta S, Continenza F, Fedele V, Bellagamba R, Cicalini S, Ammassari A, Libertone R, Zaccarelli M, Ghisetti V, Andreoni M, Ceccherini-Silberstein F, Bonora S, Di Perri G, Antinori A, Perno CF, and **Santoro Maria Mercedes**. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine singletablet regimen. *J Antimicrob Chemother.* 2017 Mar 1;72(3):855-865. doi: 10.1093/jac/dkw512. **Corresponding author. IF 4.919**
35. AJ Nanfack, D Takou, J Fokam, R Salpini, **Maria Mercedes Santoro**, G Cappelli, M Baane, SM Tetang, J Eberle, L Gürtler, F Ceccherini-Silberstein, JN Torimiro, V Colizzi, CF Perno and A Ndjolo. HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design. *Curr HIV Res.* 2016 Dec 29. [Epub ahead of print] **IF. 1.612**
36. Zaccarelli M*, **Santoro Maria Mercedes***, Armenia D, Borghi V, Gennari W, Gori C, Forbici F, Bertoli A, Fabeni L, Giannetti A, Cicalini S, Bellagamba R, Andreoni M, Mastroianni CM, Mussini C, Ceccherini-Silberstein F, Perno CF, and Antinori A. Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. *Journal of Clinical Virology* 2016, vol. 82, p. 94-100, ISSN: 1386-6532, doi: 10.1016/j.jcv.2016.07.007 ***Equal contribution. Corresponding author. IF 3.051**
37. D Armenia, D Di Carlo, G Maffongelli, V Borghi, C Alteri, F Forbici, A Bertoli, C. Gori, M Giuliani, E Nicastrì, M Zaccarelli, C Pinnetti, S Cicalini, G D'Offizi, F Ceccherini-Silberstein, C Mussini, A Antinori, M Andreoni, CF Perno, and **Maria Mercedes Santoro**. Virological response and resistance profile in HIV- infected patients starting darunavir containing regimens. *HIV Med.* 2017 Jan;18(1):21-32. doi: 10.1111/hiv.12388. Epub 2016 Jun 28. **Corresponding author. IF 3.257**
38. **Santoro Maria Mercedes**, and Perno CF. Clinical relevance of genotypic resistance testing today. *NEW MICROBIOLOGICA* 2016, vol. 39, p. 91-92, ISSN: 1121-7138. **IF. 1.568**
39. Gregson J, Tang M; Ndembu N,..... **Maria Mercedes Santoro**, ; Kantor K, Robert W Shafer RW, Gupta RK, on behalf of the TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicenter retrospective cohort study. *Lancet Infect Dis.* 2016 May;16(5):565-575. doi: 10.1016/S1473-3099(15)00536-8. Epub 2016 Jan 29. **Free PMC Article. IF. 21.372**
40. J Fokam, D Takou,1 **Maria Mercedes Santoro**, HZ Akonie, C Kouanfack, F Ceccherini-Silberstein, V Colizzi, CF Perno, and A Ndjolo. Population-Based Surveillance of HIV-1 Drug Resistance in Cameroonian Adults Initiating Antiretroviral Therapy According to the World Health Organization Guidelines. *AIDS Res Hum Retroviruses.* 2016 Apr;32(4):329-33. doi: 10.1089/AID.2015.0065. Epub 2016 Jan 20. **Corresponding author. IF. 1.603**

41. Maffongelli G, Alteri C, Gentilotti E, Bertoli A, Ricciardi A, Malagnino V, Svicher V, **Santoro Maria Mercedes**, Dori L, Perno CF, Andreoni M, Sarmati L. Impact of HIV-1 Tropism on the Emergence of non-AIDS Events in HIV-Infected Patients Receiving Fully Suppressive Antiretroviral Therapy. *AIDS*. 2016 Mar 13;30(5):731-41. doi: 10.1097/QAD.0000000000000977. **IF. 5.003**
42. A De Luca, P Flandre, D Dunn, M Zazzi, A Wensing, **Maria Mercedes Santoro**, HF Günthard, L Wittkop, T Kordossis, F Garcia, A Castagna, CF Perno, A Cozzi-Lepri, D Churchill, S De Wit, Wolfgang Fuchs, A Imaz, C Mussini, N Obel, B Roca, E Schülter, C Torti, A van Sighem, R Zangerle, and D Descamps on behalf of CHAIN and COHERE in Eurocoord working group. Improved Darunavir Genotypic Mutation Score Predicting Treatment Response for HIV- subtype B and non-B Infected Patients Receiving a Salvage Regimen. *J Antimicrob Chemother*. 2016 May;71(5):1352-60. doi: 10.1093/jac/dkv465. Epub 2016 Jan 28. PMID:26825119. **IF. 5.071**
43. R Salpini, J Fokam, L Ceccarelli, **Maria Mercedes Santoro**, A Nanfack, SM Sosso, M Kowo, V Cento, J Torimiro, L Sarmati, M Andreoni, V Colizzi, CF Perno, and O Njoya. High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians. *Curr HIV Res*. 2016;14(2):165-71. **IF 1.612**
44. Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, Gori A, Rusconi S, **Santoro Maria Mercedes**, Clementi M, Perno CF, d'Arminio Monforte A, Maggiolo F, Castagna A, De Luca A, Galli M, Giacomelli A, Borderi M, Guaraldi G, Calcagno A, Di Perri G, Bonora S, Mussini C, Di Biagio A, Puoti M, Bruno R, Zuccaro V, Antinori A, Cinque P, Croce D, Restelli U, Rizzardini G, Lazzarin A. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. *New Microbiol*. 2015 Nov;38(4):443-90. **IF. 1.603**
45. L Fabeni, C Alteri, N Orchi, C Gori, A Bertoli, F Forbici, F Montella, A Pennica, G De Carli, M Giuliani, F Continenza, C Pinnetti, E Nicastrì, F Ceccherini-Silberstein, CM Mastroianni, E Girardi, M Andreoni, A Antinori, **Maria Mercedes Santoro**, and CF Perno. Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains characterized by NNRTI-related mutations among Newly Diagnosed Men in Central Italy. *PLoS One*. 2015 Aug 13;10(8):e0135325. doi: 10.1371/journal.pone.0135325. eCollection 2015. **IF 3.54**
46. Fabeni L, Berno G, Svicher V, Ceccherini-Silberstein F, Gori C, Bertoli A, Mussini C, Lichtner M, Zaccarelli M, Ammassari A, Pinnetti C, Cicalini S, Mastroianni CM, Andreoni M, Antinori A, Perno CF, and **Santoro Maria Mercedes**. Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia. *J Clin Microbiol*. 2015 Jul 1. pii: JCM.00893-15. [Epub ahead of print] PMID:26135872 **Corresponding author**. **IF 3.631**
47. D Armenia, L Fabeni, C Alteri, D Di Pinto, D Di Carlo, A Bertoli, C Gori, S Carta, V Fedele, F Forbici, R D'Arrigo, V Svicher, G Berno, D Pizzi, E Nicastrì, L Sarmati, C Pinnetti, A Ammassari, G D'Offizi, A Latini, M Andreoni, A Antinori, F Ceccherini-Silberstein, CF Perno and **Maria Mercedes Santoro**. HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations also in patients with low-level viremia. *Journal of Antimicrobial Chemotherapy* 2015 Jun;70(6):1865-73. doi: 10.1093/jac/dkv029. Epub 2015 Feb 23. **Corresponding author**. **IF 4.919**
48. J Vingerhoets, V Calvez, P Flandre, A-G Marcelin, F Ceccherini-Silberstein, C-F Perno, **Maria Mercedes Santoro**, R Bateson, M Nelson, A Cozzi-Lepri, J Grarup, and J Lundgren. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. *HIV Med*. 2015 Jan 14. doi: 10.1111/hiv.12218. **IF 3.341**

49. Mirabelli C, Surdo M, Van Hemert F, Lian Z, Salpini R, Cento V, Cortese MF, Aragri M, Pollicita M, Alteri C, Bertoli A, Berkhout B, Micheli V, Gubertini G, **Maria Mercedes Santoro**, Romano S, Visca M, Bernassola M, Longo R, De Sanctis GM, Trimoulet P, Fleury H, Marino N, Mazzotta F, Cappiello G, Spanò A, Sarrecchia C, Zhang JM, Andreoni M, Angelico M, Verheyen J, Perno CF, Svicher V. Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. *J Infect.* 2015 Mar;70(3):288-98. doi: 10.1016/j.jinf.2014.10.015. Epub 2014 Nov 6. **IF 3.39**
50. J.L. Blanco, J. Montaner, V.C. Marconi, **Maria Mercedes Santoro**, A.E. Campos-Loza, R.W. Shafer, M.D. Miller, R. Paredes, R. Harrigan, M.L. Nguyen, C.F. Perno, L.A. Gonzalez-Hernandez and J.M. Gatella. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir+emtricitabine/lamivudine+efavirenz administered on a multiple tablet therapy. *AIDS.* 2014 Nov 13;28(17):2531-9. **IF 6.557**
51. Armenia D, Soulie C, Di Carlo D, Fabeni L, Gori C, Forbici F, Svicher V, Bertoli A, Sarmati L, Giuliani M, Latini A, Boumis E, Zaccarelli M, Bellagamba R, Andreoni M, Marcelin AG, Calvez V, Antinori A, Ceccherini-Silberstein F, Perno CF, and **Maria Mercedes Santoro**. A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. *PLoS One.* 2014 Aug 25;9(8):e105853. doi: 10.1371/journal.pone.0105853. **Corresponding author.** **IF 3.234**
52. V Svicher, C Alteri, **Maria Mercedes Santoro**, F Ceccherini-Silberstein, AG Marcelin, V Calvez, CF Perno. The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature. *J Infect.* 2014 May 15. pii: S0163-4453(14)00127-3. doi: 10.1016/j.jinf.2014.05.001. **IF. 4.017**
53. **Maria Mercedes Santoro**, L Fabeni, D Armenia, C Alteri, D Di Pinto, F Forbici, A Bertoli, D Di Carlo, C Gori, S Carta, V Fedele, R D'Arrigo, G Berno, A Ammassari, C Pinnetti, E Nicastrì, A Latini, C Tommasi, E Boumis, N Petrosillo, G D'Offizi, M Andreoni, F Ceccherini-Silberstein, A Antinori, and CF Perno. Reliability and Clinical Relevance of the HIV-1 Drug-Resistance Test in Patients with Low Viremia Levels. *Clin Infect Dis.* 2014 Apr;58(8):1156-64. doi: 10.1093/cid/ciu020. Epub 2014 Jan 14. **IF. 8.886**
54. M Giuliani*, **Maria Mercedes Santoro***, A Lo Presti, E Cella, P Scognamiglio, A Lai, A Latini, L Fabeni, C Gori, C Pinnetti, E Girardi, CF Perno, G Zehender, and M Ciccozzi. Circulation of HIV-1 CRF02_AG among MSM Population in Central Italy: A Molecular Epidemiology-Based Study. *BioMed Research International*, Volume 2013 (2013), Article ID 810617. <http://dx.doi.org/10.1155/2013/810617>. ***Equal contribution.** **IF 2.880**
55. Alteri C, Artese A, Beheydt G, **Maria Mercedes Santoro**, Costa G, Parrotta L, Bertoli A, Gori C, Orchi N, Girardi E, Antinori A, Alcaro S, d'Arminio Monforte A, Theys K, Vandamme AM, Ceccherini-Silberstein F, Svicher V, Perno CF. Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. *J Antimicrob Chemother.* 2013 May 29. **IF. 5.338**
56. **Santoro Maria Mercedes**, C Sabin, F Forbici, L Bansi, D Dunn, E Fearnhill, E Boumis, E Nicastrì, A Antinori, G Palamara, A Callegaro, D Francisci, A Zoncada, F Maggiolo, M Zazzi, CF Perno, F Ceccherini-Silberstein, and C Mussini. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. *HIV Medicine.* 2013 Oct;14(9):571-7. doi: 10.1111/hiv.12044. Epub 2013 May 13. **IF. 3.155**

57. **Santoro Maria Mercedes**, D Armenia, C Alteri, P Flandre, A Calcagno, M Santoro, C Gori, L Fabeni, R Bellagamba, V Borghi, F Forbici, A Latini, G Palamara, R Libertone, V Tozzi, E Boumis, C Tommasi, C Pinnetti, A Ammassari, E Nicastrì, A Buonomini, V Svicher, M Andreoni, P Narciso, C Mussini, A Antinori, F Ceccherini-Silberstein, G Di Perri and CF Perno. Impact of pre-therapy viral load on virological response to modern first-line HAART”. *Antivir Ther.* 2013;18(7):867-76. doi: 10.3851/IMP2531. Epub 2013 Jan 23. **IF. 3.073**
58. V Svicher, V Cento, G Rozera, I Abbate, **Maria Mercedes Santoro**, D Armenia, L Fabeni, A Bruselles, G Palamara, V Micheli, G Rizzardini, C Gori, F Forbici, G Ippolito, M Andreoni, A Antinori, F Ceccherini-Silberstein, MR Capobianchi, and CF Perno. The Genotypic False Positive Rate Determined by V3 Population Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing. *PLoS One.* 2013;8(1):e53603. doi: 10.1371/journal.pone.0053603. Epub 2013 Jan 14. **Free PMC Article. IF. 3.73**
59. Ciccozzi M, **Santoro Maria Mercedes**, Giovanetti M, Andrissi L, Bertoli A, Ciotti M. HIV-1 Non-B subtypes in Italy: a growing trend. *New Microbiol.* 2012 Oct;35(4):377-86. Epub 2012 Oct 1. **Review. Free PMC Article. IF. 1**
60. **Santoro Maria Mercedes**, Armenia D, Fabeni L, Santoro M, Gori C, Forbici F, Svicher V, Bertoli A, Dori L, Surdo M, Balestra E, Palamara G, Girardi E, Angarano G, Andreoni M, Narciso P, Antinori A, Ceccherini-Silberstein F, Perno CF. The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. *Clin Microbiol Infect.* 2012 Aug;18(8):E289-98. doi: 10.1111/j.1469-0691.2012.03905.x. Epub 2012 Jun 8. **Free PMC Article. IF. 4.54**
61. Ceccarelli L, Salpini R, Moudourou S, Cento V, **Santoro Maria Mercedes**, Fokam J, Takou D, Nanfack A, Dori L, Torimiro J, Sarmati L, Andreoni M, Perno CF, Colizzi V, Cappelli G. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon. *J Med Virol.* 2012 May;84(5):721-7. doi: 10.1002/jmv.23244. **IF. 2.82**
62. **Santoro Maria Mercedes**, Alteri C, Ronga L, Flandre P, Fabeni L, Mercurio F, D'Arrigo R, Gori C, Palamara G, Bertoli A, Forbici F, Salpini R, Boumis E, Tozzi V, Visco-Comandini U, Zaccarelli M, Van Houtte M, Pattery T, Narciso P, Antinori A, Ceccherini-Silberstein F, Perno CF. Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy. *AIDS Res Hum Retroviruses.* 2012 Oct;28(10):1285-93. Epub 2012 Apr 18. **Free PMC Article. Corresponding author. IF. 2.246**
63. Alcaro S, Alteri C, Artese A, Ceccherini-Silberstein F, Costa G, Ortuso F, Bertoli A, Forbici F, **Santoro Maria Mercedes**, Parrotta L, Flandre P, Masquelier B, Descamps D, Calvez V, Marcelin AG, Perno CF, Sing T, Svicher V. Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine. *Chem Med Chem.* 2011 Dec 9;6(12):2203-13. doi: 10.1002/cmdc.201100362. Epub 2011 Sep 27. **IF. 3.151**
64. C Alteri, **Santoro Maria Mercedes**, I Abbate, G Rozera, A Bruselles, B Bartolini, C Gori, F Forbici, N Orchi, V Tozzi, G Palamara, A Antinori, P Narciso, E Girardi, V Svicher, F Ceccherini-Silberstein, MR Capobianchi, and CF Perno. “Sentinel” mutations in standard population sequencing can predict the presence of HIV-1 Reverse Transcriptase major mutations detectable only by ultra-deep pyrosequencing. *Journal of Antimicrobial Chemotherapy.* 2011 Nov;66(11):2615-23. Epub 2011 Sep 2. **Free PMC Article; IF. 5.068**
65. J Fokam, R Salpini, **Santoro Maria Mercedes**, V Cento, CF Perno, V Colizzi, PM Ndumbe, C Fokunang Ntungen, SM Ndiang Tetang, AJ Nanfack, DA Takou Komego, and G Cappelli. Drug Resistance Among Drug-naïve and First-line Antiretroviral Treatment-failing Children in Cameroon. *Pediatric Infectious Disease Journal.* 2011 Dec;30(12):1062-8. **IF. 3.577**

66. A De Luca, S Di Giambenedetto, R Maserati, N Gianotti, P Narciso, A Antinori, G Di Perri, M Prosperi, F Baldanti, V Micheli, M Zazzi, CF Perno and **Maria Mercedes Santoro** for the *TMC114-C226 and the ARCA study groups*. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score. *Antiviral Therapy*. 2011;16(4):489-97. **IF. 3.161**
67. J Fokam, R Salpini, **Santoro Maria Mercedes**, V Cento, R D'Arrigo, C Gori, CF Perno, V Colizzi, A Nanfack, LC Gwom, G Cappelli, and D. Takou. Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. *Archive of Virology*. 2011 Jul;156(7):1235-43. **IF. 2.111**
68. N Mendonca Collaço Vêras*, **Santoro Maria Mercedes***, RR Gray, AJ Tatem, A Lo Presti, F Olearo, G Cappelli, V Colizzi, D Takou, J Torimiro, G Russo, AP Callegaro, R Salpini, R D'Arrigo, CF Perno, MM Goodenow, M Ciccozzi, and M Salemi. Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in Italy. *AIDS Res Hum Retroviruses*. 2011 Nov;27(11):1173-82. doi: 10.1089/AID.2010.0333. Epub 2011 May 6. ***Equal contribution. Free PMC Article; IF. 2.246**
69. Ciccozzi M, Vujošević D, Lo Presti A, Mugoša B, Vratnica Z, Lai A, Laušević D, Drašković N, Marjanovic A, Cella E, **Santoro Maria Mercedes**, Alteri C, Fabeni L, Ciotti M, Zehender G. Genetic Diversity of HIV-1 in Montenegro. *AIDS Res Hum Retroviruses*. 2011 Aug;27(8):921-4. Epub 2010 Dec 31. **IF. 2.082**
70. JM Schapiro, J Scherer, CA Boucher, JD Baxter, H Gellerman, CF Perno, F Maggiolo, **Santoro Maria Mercedes**, and DB Hall. Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. *Antiviral Therapy*. 2010;15(7):1011-9. **IF. 3.774**
71. V Svicher, C Alteri, A Artese, F Forbici, **Santoro Maria Mercedes**, D Schols, K Van Laethem, S Alcaro, G Costa, C Tommasi, M Zaccarelli, P Narciso, A Antinori, F Ceccherini-Silberstein, J Balzarini, and CF Perno. Different Evolution of Genotypic Resistance Profiles to Emtricitabine versus Lamivudine in Tenofovir Containing Regimens. *Journal of Acquired Immune Deficiency Syndrome*. 2010 Nov 1;55(3):336-44. **IF 4.262**
72. G Zehender, E Ebranati, A Lai, **Santoro Maria Mercedes**, C Alteri, M Giuliani, G Palamara, CF Perno, M Galli, A Lo Presti, M Ciccozzi. Population dynamics of HIV-1 subtype B in a cohort of men having sex with men in Rome, Italy. *J Acquir Immune Defic Syndr*. 2010 Oct 1;55(2):156-60. **IF 4.262**
73. C Tommasi, F Ceccherini-Silberstein, R D'Arrigo, R Bellagamba, M Tempestilli, C Dessi, **Santoro Maria Mercedes**, F Forbici, L Pucillo, CF Perno, and P Narciso. Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir. *Scand Journal Infectious Disease*, 2010, Jan; 0(0):1-3. **IF. 1.209**
74. M Zaccarelli, A Antinori, A Cozzi-Lepri, C Mussini, G Palamara, **Santoro Maria Mercedes**, A d'Arminio Monforte, CF Perno, and F Ceccherini-Silberstein. Is there any potential for first line Etravirine use? Analysis from a large dataset of ART-naïve HIV infected patients undergoing resistance test. *Journal of Acquired Immune Deficiency Syndrome*, 2010 Jan 1;53(1):150-1. **IF 4.262**
75. M Trignetti, T Sing, V Svicher, **Maria Mercedes Santoro**, F Forbici, R D'Arrigo, MC Bellocchi, M Santoro; P Marconi, M Zaccarelli, MP Trotta, R Bellagamba, P Narciso, A Antinori, T Lengauer, and CF Perno. Dynamics of NRTI Resistance Mutations During Therapy Interruption. *AIDS Research and Human Retroviruses*, 2009 Jan;25(1):57-64. **IF. 2.178**

76. **Santoro Maria Mercedes**, A Bertoli, P Lorenzini, F Ceccherini-Silberstein, N Gianotti, C Mussini, C Torti, G Di Perri, G Barbarini, T Bini, S Melzi, P Caramello, R Maserati, P Narciso, V Micheli, A Antinori, CF Perno, and the CARE Study Group. Two different patterns of mutations involved in the genotypic resistance score for atazanavir boosted versus atazanavir unboosted by ritonavir in multiply failing patients. *Infection*. 2009 Jun;37(3):233-43. Epub 2009 Jan 23. **IF. 2.051**
77. Giuliani M, S Montieri, G Palamara, A Latini, C Alteri, CF Perno, **Santoro Maria Mercedes**, G Rezza, and M Ciccozzi. Non-B HIV-1 subtypes among Men Who Have Sex With Men in Rome, Italy. *AIDS Research and Human Retroviruses*. 2009 Jan; 25(2):157-64. **IF. 2.178**
78. **Santoro Maria Mercedes**, M Ciccozzi, C Alteri, S Montieri, I Alexiev, I Dimova, F Ceccherini-Silberstein, D Beshkov, G Rezza, and CF Perno. Characterization of Drug-Resistance Mutations in HIV-1 Isolates from Drug-Naive and ARV Treated Patients in Bulgaria. *AIDS Research and Human Retroviruses*, 2008 Sep;24(9):1133-1138. **Corresponding author**. **Free PMC Article**. **IF. 2.024**
79. M Salemi, MM Goodenow, S Montieri, Tulio de Oliveira, **Santoro Maria**, D Beshkov, I Alexiev, I Elenkov, I Elenkov, T Yakimova, T Varleva, G Rezza, and M Ciccozzi. The HIV-1 epidemic in Bulgaria involves multiple subtypes and is sustained by continuous viral inflow from West and East European countries. *AIDS Research and Human Retroviruses*, 2008 Jun; 24(6):771-779. **Free PMC Article**. **IF. 2.024**
80. V Svicher, S Aquaro, R D'Arrigo, A Artese, S Dimonte, S Alcaro, **Santoro Maria Mercedes**, G Di Perri, S Lo Caputo, R Bellagamba, M Zaccarelli, U Visco-Comandini, A Antinori, P Narciso, F Ceccherini-Silberstein, and CF Perno. Specific enfuvirtide associated mutational pathways in HIV-1 gp41 are significantly correlated with a gain of CD4 cell count despite virological failure. *The Journal of Infectious Diseases*, 2008 May 15;197(10):1408-1418. **Free PMC Article**. **IF. 5.682**; **Scientific Award ReAd files 2008**.
81. **Santoro Maria Mercedes**, A Bertoli, P Lorenzini, A Lazzarin, R Esposito, G Carosi, G Di Perri, G Filice, M Moroni, G Rizzardini, P Caramello, R Maserati, P Narciso, A Cargnel, A Antinori, CF Perno, and the CARE Study Group. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARE Study. *AIDS patient care and STDs*, 2008 January;22(1):7-16. **Corresponding author**. **IF. 2.392**
82. F Ceccherini-Silberstein, V Svicher, T Sing, A Artese, **Santoro Maria Mercedes**, C Gori, A Bertoli, S Alcaro, G Palamara, A d'Arminio Monforte, A Antinori, T Lengauer, and CF Perno, ICoNA Study Group, INMI-Collaborative Group for Clinical Use of HIV Genotype Resistance Test. Characterization and Structural Analysis of Novel Mutations in HIV-1 Reverse Transcriptase Involved in the Regulation of Resistance to Non-Nucleoside Inhibitors. *Journal of Virology* 2007 Aug 8. **Free PMC Article**; **IF. 5.332**; **Cites 72**. **Scientific Award G.B. Rossi 2008**
83. V Svicher, T Sing, **Santoro Maria Mercedes**, F Forbici, F Rodriguez-Barrios, A Bertoli, N Beerenwinkel, Maria Concetta Bellocchi, F Gago, A d'Arminio Monforte, A Antinori, T Lengauer, F Ceccherini-Silberstein, and Carlo Federico Perno. Involvement of novel HIV-1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. *Journal of Virology*, July 2006; 80 (14): 7186-7198. **Free PMC Article**; **IF. 5.341**
84. **Santoro Maria Mercedes**, V Svicher, C Gori, M Zaccarelli, V Tozzi, F Forbici, R d'Arrigo, MP Trotta, MC Bellocchi, U Visco-Comandini, A Cenci, A Bertoli, P Narciso, A Antinori, CF Perno, and F Ceccherini-Silberstein. Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy. *The New Microbiologica*, April 2006; 29 (2):89-100. **IF. 0.806**
85. F Ceccherini-Silberstein, F Gago, **Santoro Maria**, C Gori, V Svicher, F Rodriguez-Barrios, M Ciccozzi, R D'Arrigo, A Bertoli, S Boros, A d'Arminio Monforte, J Balzarini, A Antinori, and CF

Perno. High Sequence Conservation of HIV-1 reverse transcriptase under drug pressure despite a continuous appearance of mutations. *Journal of Virology*. August 2005; 79(16):10718-29. **Free PMC Article; IF. 5.178**

86. V Svicher, F Ceccherini-Silberstein, F Erba, **Santoro Maria Mercedes**, C Gori, MC Bellocchi, S Giannella, MP Trotta, A d'Arminio Monforte, 5A Antinori, and CF Perno. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. *Antimicrobial Agents and Chemotherapy*. May 2005; 49(5):2015-25. **Free PMC Article; IF. 4.379**

87. **Santoro Maria**, F Ceccherini-Silberstein, C Gori, V Svicher, F Forbici, MC Bellocchi, R d'Arrigo, A Bertoli, S Giannella, MP Trotta, S Bonfigli, A Antinori, and CF Perno. Temporal change in the use of genotypic resistance testing over the years 1999-2003. *The New Microbiologica*. 2004; 27(Suppl 1):141-4. **IF. 1**

88. A Buschini, A Martino, B Gustavino, M Monfrinotti, P Poli, C Rossi, **Santoro Maria**, AJM Dörr, and M Rizzoni. Comet Assay and micronucleus test in circulating erythrocytes of *Cyprinus carpio* specimen exposed in situ to lake waters treated with disinfectants for potabilization. *Mutation Research*. 2004 Feb 14;557(2):119-29. **IF. 2.020**

Publications In Collaborative Groups

89. d'Arminio Monforte A, Cozzi-Lepri A, Di Biagio A, Marchetti G, Lo Caputo S, Rusconi S, Gianotti N, Mazzotta V, Mazzarello G, Costantini A, Castagna A, Antinori A; ICONA Foundation Study Group (d'Arminio Monforte A, Antinori A, ... **Santoro Maria Mercedes**, Starnini G, Ialungo A). Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. *J Antimicrob Chemother*. 2019 Jan 29. doi: 10.1093/jac/dky566. [Epub ahead of print] PubMed PMID: 30698801. **IF 5.217**

90. Mondì A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group (d'Arminio Monforte A, Antinori A, ... **Santoro Maria Mercedes**, Starnini G, Ialungo A). Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. *J Int AIDS Soc*. 2019 Jan;22(1):e25227. doi: 10.1002/jia2.25227. PubMed PMID:30663278; PubMed Central PMCID: PMC6340053. **IF 5.131**

91. Ceccherini-Silberstein F, Cozzi Lepri A, Alteri C, Merlini E, Surdo M, Marchetti G, Capobianchi MR, De Luca A, Gianotti N, Viale P, Andreoni M, Antinori A, Perno CF, d'Arminio Monforte A; ICONA Foundation Study Group (d'Arminio Monforte A, Antinori A, ... **Santoro Maria Mercedes**, Starnini G, Ialungo A). Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. *J Antimicrob Chemother*. 2018 Sep 20. doi: 10.1093/jac/dky350. [Epub ahead of print] PubMed PMID: 30247724. **IF 5.217**

92. Taramasso L, Di Biagio A, Maggiolo F, Tavelli A, Lo Caputo S, Bonora S, Zaccarelli M, Caramello P, Costantini A, Viscoli C, d'Arminio Monforte A, Cozzi-Lepri A; Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group (Andreoni M, Angarano G, ... **Santoro Maria Mercedes**, Pellizer G, Manfrin V). First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. *HIV Med*. 2018 May 30. doi: 10.1111/hiv.12628. [Epub ahead of print] PubMed PMID: 29846042. **IF 2.932**

93. Mussini C, Lorenzini P, Cozzi-Lepri A, Marchetti G, Rusconi S, Gori A, Nozza S, Lichtner M, Antinori A, Cossarizza A, d'Arminio Monforte A; Icona Foundation Study Group (d'Arminio Monforte A, Antionori A, ... **Santoro Maria Mercedes**, Starnini G, Ialungo A). Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational

cohort study. BMC Med. 2018 May 29;16(1):79. doi: 10.1186/s12916-018-1046-2. PubMed PMID: 29807541; PubMed Central PMCID: PMC5972434. **IF 9.088**

94. Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group (d'Arminio Monforte A, Andreoni M, Angarano G, ... **Santoro Maria Mercedes**, ... Pellizzer G, Manfrin V). Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤ 50 cp/mL. Infection. 2017 Aug;45(4):521-528. doi: 10.1007/s15010-017-1018-z. Epub 2017 May 5. PubMed PMID: 28477212. **IF 2.773**

95. Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group (Calvo G, Bonnet F, ... **Santoro Maria Mercedes**, ... Wandeler G, Yerly S.). Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25083. PubMed PMID: 29509305; PubMed Central PMCID: PMC5839235. **IF 5.131**

96. Svicher V, Marchetti G, Ammassari A, Ceccherini-Silberstein F, Sarmati L; Impact Study Group [Ammassari A, Andreoni M, ... **Santoro Maria**, ... , Zaccarelli M, Zazzi M]. Novelty in Evaluation and Monitoring of Human Immunodeficiency Virus-1 Infection: Is Standard Virological Suppression Enough for Measuring Antiretroviral Treatment Success? AIDS Rev. 2017 Sep 19;19(3). [Epub ahead of print] **IF 2.775**

97. Puoti M, Lorenzini P, Cozzi-Lepri A, Gori A, Mastroianni C, Rizzardini G, Mazzarello G, Antinori A, d'Arminio Monforte A, Girardi E; Icona Foundation Study Group [d'Arminio Monforte A, Andreoni M, ... **Santoro Maria Mercedes**, ... Londero A, Pellizzer G, Manfrin V]. Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clin Microbiol Infect. 2016 Dec 9. pii: S1198-743X (16) 30608-5. doi: 10.1016/j.cmi.2016.12.003. [Epub ahead of print] **IF 5.292**

98. Antinori A, Marcotullio S, Andreoni M, Chirianni A, d'Arminio Monforte A, Di Biagio A, Galli M, Mazzotta F, Mussini C, Puoti M, Lazzarin; Italian HIV Guidelines Working Group [Adriana A, Gioacchino A, Orlando A, ... **Santoro Maria**, ... Vullo V, Zaccarelli M, Zuccotti VG]. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. New Microbiol. 2016 Apr;39(2):93-109. **IF 1.568**

99. Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group [Moroni M, Angarano G, Antinori A, ... **Santoro Maria**, ... , Londero A, Pellizzer G, Manfrin V]. Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. PLoS One. 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015. **IF. 3.234**

100. Di Maio VC, Cento V, Di Paolo D, ...; HCV Italian Resistance Network Study Group (Mariani R, ... **Santoro Maria Mercedes**, ... Tarquini P). HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. J Antimicrob Chemother. 2016 Mar;71(3):739-50. doi: 10.1093/jac/dkv403. Epub 2015 Dec 17. **IF. 4.919**

101. Antinori A, Marcotullio S, Andreoni M, Ammassari A, d'Arminio Monforte A, Galli M, Girardi E, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group [Ammassari A, Angarano G, Armignacco O, ... **Santoro Maria**, ... , Zaccarelli M, Zuccotti GV]. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. New Microbiol. 2015 Jul;38(3):299-328. **IF. 1.603**

102. Antinori A, Andreoni M, Perno CF, Lazzarin A; HEFFICON Study Group [Ammassari A, Bonfanti P, Bonora S, Borderi M, Capobianchi MR, Castagna A, Clementi M, Cinque P, d'Arminio Monforte A, Di Perri G, Galli M, Gori A, Maggi P, Mastroianni C, Mussini C, Nicastri E, Puoti M,

Rusconi S, **Santoro Maria**, Tambussi G]. HEFFICON: HIV Effectiveness Italian Conference. New Microbiol. 2015 May;38(2):149-84. **IF. 1.603**

103. Scientific Coordination Committee, Marcotullio S, Andreoni M, Antinori A, d'Arminio Monforte A, Di Perri G, Galli M, Ippolito G, Perno CF, Rizzardini G, Lazzarin A; Rapporteur Committee, Cinque P, Fares G, Foglia E, Gervasoni C, Murri R, Nozza S, Rusconi S. Multidisciplinary Italian Expert Panel on LDR [..Other Members: ... Sangiovanni V, **Santoro Maria**, Scaggiante R,...]. The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. New Microbiol. 2012 Jul;35(3):259-77. **Free PMC Article; IF. 1**

104. R Granich, S Gupta, AB Suthar, C Smyth, D Hoos, M Vitoria, M Bavicchi Simao, C Hankins, B Schwartlander, R Ridzon, B Bazin, B Williams, YR Lo, C McClure, J Montaner, G Hirschall; on behalf of the ART in Prevention of HIV and TB Research Writing Group [=....., LI Gardner, **Santoro Maria Mercedes**, MLNewell,..]. Antiretrovirals therapy in Prevention of HIV and TB: Update on Current Research Efforts. Curr HIV Res. 2011 Sep;9(6):446-69. **IF. 1.923**

105. A Antinori, MP Trotta, P Lorenzini, C Torti, N Gianotti, F Maggiolo, F Ceccherini-Silberstein, C Torti, P Nasta, A Castagna, A De Luca, C Mussini, M Andreoni, and CF Perno for the **GNOMO Study Group** [=Roma:, P Lorenzini, **Santoro Maria Mercedes**, A Conte,, list available in the supplementary information of the journal]. Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation. Antivir Ther. 12(8):1175-83 (2007). **IF 4.547**

Publications without Impact factor

106. J Fokam, **Maria Mercedes Santoro**, I Chimbiri, J Chindiura, R Deula, A Rombe, R Massari, A Lungu, and CF Perno. Programmatic Challenges in Implementing PMTCT Option B+ and Pediatric HIV Care: Baseline Assessment from “Save the Families for Africa” in Malawi. Health Sciences and diseases. Vol 20, No 3 (2019). ISSN: **2309-6535**. **Free PMC Article**.

107. C Alteri, M Surdo, VC Di Maio,, **Maria Mercedes Santoro**,, A Artese, CF Perno, and V Svicher. The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+ emtricitabine-containing HAART both in vivo and in vitro. J Glob Antimicrob Resist. 2016 Jul 25;7:1-7. doi: 10.1016/j.jgar.2016.06.005. [Epub ahead of print]

108. **Santoro Maria Mercedes**, Perno CF. HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiol. 2013 Jun 17;2013:481314. doi: 10.1155/2013/481314. Print 2013. **Review. Free PMC Article**.